# Reply: SABRE for airway quantification in idiopathic pulmonary fibrosis: clarifications, limitations, and next steps

## TL;DR

The authors respond to feedback on SABRE, an imaging tool for measuring airway changes in idiopathic pulmonary fibrosis, and discuss its potential and limitations.

## Contribution

The paper clarifies SABRE's role as a promising imaging biomarker and outlines necessary steps for its clinical adoption.

## Key findings

- SABRE is a robust imaging biomarker for airway quantification in IPF.
- Prospective validation and integration into clinical decision-making are needed for full adoption.

## Abstract

We thank Z. Zhang and co-workers, and T. Zhang for their thoughtful and constructive comments on our recent study of SABRE (Smart Airway Biomarker Recognition Engine) for airway quantification in idiopathic pulmonary fibrosis (IPF) [1]. Below, we provide a point-by-point response to the key issues raised.

SABRE is a robust imaging biomarker for airway quantification in idiopathic pulmonary fibrosis, while its full clinical adoption depends on prospective validation, broader clinical endpoints and integration into decision-making frameworks
https://bit.ly/3VVacfK